Good Question. Kevetrin has essentially been p
Post# of 72445
(Total Views: 347)
Posted On: 07/19/2018 2:09:41 PM
Good Question.
Kevetrin has essentially been put to the "back burner" due to the sheer amount of money it is necessary to move to the next phases. In my opinion management understands the opportunity of Kevetrin but also understand the dilution necessary to advance the next phases as well. Two options exist for Kevetrin and both are related to Prurisol results.
1. Prurisol results are extraordinary and complete buyout of IP and all assets are acquired by purchasing Pharma. (B, P, K)
2. Prurisol results are moderate or do not meet secondary end points and the Pharma with first right of refusal for buyout or another bidding company either partners for B-OM or the franchise as a whole. They provide up front payment, milestone payments and royalty agreements. Aspire is also utilized for milestone payments under the current agreement. IP then takes the multi million dollars received through Milestone Aspire Arrangement and Up-Front partnership payment to divide for further advancement of P, K and possibly other B indications...
- Kevetrin will advance to additional phase for indications and possible utilization in conjunction with an already approved drug.
- Prurisol will be reformulated for indications allowed under the primary endpoints that were already met with additional outcomes that will be seen through the questionnaires. Ex. Dermatological Cream to help with psoriasis caused itching and inflammation.
Hope this answers your question...
-All My Opinion Based On DD-
Kevetrin has essentially been put to the "back burner" due to the sheer amount of money it is necessary to move to the next phases. In my opinion management understands the opportunity of Kevetrin but also understand the dilution necessary to advance the next phases as well. Two options exist for Kevetrin and both are related to Prurisol results.
1. Prurisol results are extraordinary and complete buyout of IP and all assets are acquired by purchasing Pharma. (B, P, K)
2. Prurisol results are moderate or do not meet secondary end points and the Pharma with first right of refusal for buyout or another bidding company either partners for B-OM or the franchise as a whole. They provide up front payment, milestone payments and royalty agreements. Aspire is also utilized for milestone payments under the current agreement. IP then takes the multi million dollars received through Milestone Aspire Arrangement and Up-Front partnership payment to divide for further advancement of P, K and possibly other B indications...
- Kevetrin will advance to additional phase for indications and possible utilization in conjunction with an already approved drug.
- Prurisol will be reformulated for indications allowed under the primary endpoints that were already met with additional outcomes that will be seen through the questionnaires. Ex. Dermatological Cream to help with psoriasis caused itching and inflammation.
Hope this answers your question...
-All My Opinion Based On DD-
(5)
(0)